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suggesting a similar overall survival benefit for the two drugs.
Furthermore survival subset analyses in BR21 were consistent
with ISEL, with the largest survival benefits for erlotinib also seen
in the never-smoking and Asian subgroups. The objective
response rates were comparable for gefitinib and erlotinib in
these two studies (8% vs. 9%, respectively).1,2
As the ISEL result was surprising, a number of comparisons
have been made.3
In ISEL 45% of patients had progressed and only 18%
responded on the most recent chemotherapy, whereas for BR21
28% progressed and 38% had responded, the more refractory
patients may have had less chance of benefiting. Erlotinib has a
greater affinity for the receptor and was used at the MTD
(150 mg) the similar dose for gefitinib would be 700 mg not the
250 mg used in ISEL. Further work investigating patient character-
istics e.g. smoking status, identification of more sensitive popula-
tions and molecular markers will be important.
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S54. PROTEIN LYSATE ARRAY ASSESSMENT OF THERAPEUTIC
TARGETS IN SARCOMA
Dennis P.M. Hughes. Children’s Cancer Hospital at M. D. Anderson
Cancer Center, TX, USA.
Small molecule inhibitors have brought new hope for cancers
with dire prognoses. These molecular medicines turn off specific
signaling intermediaries within cells, leaving others unaffected.
Their efficacy has been demonstrated clinically with medicines
such as imatinib for CML and GI stromal tumor and erlotinib for
EGFR-dependent head and neck, lung and breast cancer. More
small molecules are being developed. To rationally apply this
development to more diseases, a rapid screening tool is required
to identify expression and activity of protein targets in an individ-
ual patient’s tumor. The technical challenges for this tool are sig-
nificant: assessing dozens, if not hundreds, of potential targets
accurately using the small amount of tissue available through
core needle biopsies. We have begun applying a novel technology
– protein lysate array analysis – to address this problem in sar-
coma. Tumor lysates are arrayed on nitrocellulose matrix using
a modified DNA arrayer, creating 100+ duplicate slides using as
little as one microgram total protein. Individual slides are assayed
with monospecific antibodies and comparisons made between
phospho- and total protein levels, identifying the activation state
of dozens of potential therapeutic targets. We have used this
technique preclinically to test the downstream effects of erlotinib
in osteosarcoma and Ewing sarcoma, identifying changes in
MAPK, mTOR, AKT and JNK pathway signaling. We will use it in
a clinical trial of an anti-ERBB medicine to assess the correlation
between disease response and changes in signaling, using paired
samples of pre- and post-treatment tissue. We envision prospec-
tive testing of tumor tissue, allowing the clinician to choose those
small molecule(s) able to inhibit the specific pathway(s) active in
an individual’s tumor.
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The treatment of lung cancer has undergone a remarkable trans-
formation over the past five years. Previously histology and ana-
tomic stage were the primary determinants of treatment. While
these still have an important role, the future of treating this dis-
ease will be based on molecular staging strategies. This will allow
us to select more effective and less toxic treatments in the initial
treatment of metastatic disease. It will also permit informed
selection of patients for adjuvant treatment. Finally aggressive
molecular staging will hopefully uncover new targets that will
result in new drugs that may one day transform lung cancer into
a chronic disease with long-term survival the rule and not the
exception.
Agents that target the epidermal growth factor receptor (EGFR)
tyrosine kinase are among the most important new drugs in use
to treat non-small cell lung cancer. Both gefitinib and erlotinib are
capable of producing remarkable tumor responses as single
agents that are durable. These dramatic responses are often asso-
ciated with mutations in the EGFR tyrosine kinase domain. In
addition when used in second and third line treatment of lung
cancer erlotinib has been shown to prolong survival in this set-
ting. This clinical benefit is best predicted by increased EGFR gene
copy number as measured by FISH.
The use of EGFR-TKI provides an exceptional opportunity for
molecular staging. EGFR mutation testing is being used to select
patients for first line treatment with both gefitinib and erlotinib.
Trials in the United States, Japan and Europe are employing this
strategy and early results should be reported by the end of 2006.
The potential to identify a population of patients who might be
able to be treated with EGFR-TKI monotherapy as first line would
potentially deliver equivalent anti-tumor activity with fewer side
effects than combination chemotherapy.
Measurement of gene copy number by FISH is being used to
select patients for treatment with EGFR-TKI treatment in several
clinical scenarios. Patients who are FISH positive are being
entered onto trials of erlotinib plus chemotherapy as first line
treatment. Adjuvant studies of chemotherapy plus erlotinib given
as sequential therapy are under review. Finally there is some con-
troversy as to the relative value of EGFR protein expression as
measured by immunoperoxidase staining. Some thoughtful
investigators feel that the best way to select adjuvant and first
line metastatic patients for TKI treatment is by using a combina-
tion of FISH and immunoperoxidase staining.
While FISH and immunoperoxidase may be important modal-
ities in the molecular staging of lung cancer, mutation testing
offers a potential benefit not available with those methods.
Patients who are resistant to EGFR-TKI treatment have been found
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